Nectar Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nectar Lifesciences reported a total comprehensive loss of Rs 29,289.10 lakhs for FY 2025-26, primarily driven by huge losses from discontinued pharma operations (Rs 53,765.51 lakhs loss before tax). The company completed a major slump sale of its pharmaceutical business to Ceph Lifesciences Private Limited in November 2025 for Rs 12,539.85 crore, booking a gain of Rs 16,337.33 lakhs under exceptional items. Following the sale, continuing operations show zero revenue as the company pivots toward real estate, holding only Rs 929.09 lakhs in other income. The company also reported a Rs 5,209.53 lakh loss on mutual fund and equity investments due to market volatility. A share buyback of 3 crore shares at Rs 27 each (Rs 8,100 lakhs) was completed in January 2026. Auditors issued an unmodified opinion with emphasis of matter on going concern assessment, the slump sale transaction, and substantial investment losses.
The company is undergoing a fundamental transformation after selling its core pharma business, leaving it with no operating revenue but significant cash reserves. The large net loss and going concern emphasis from auditors indicate significant risks for shareholders, though the company claims adequate liquidity after debt repayment.